• 1

    Thio CL, Seaberg EC, Skolasky R, Phair J, Visscsher B, 2002. Munoz and Thomas DL. HIV-1, hepatitis B virus, and the risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360 :1921–1926.

    • Search Google Scholar
    • Export Citation
  • 2

    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, Lu B, Cheng AK, 903 Study Team, 2004. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 189 :1185–1192.

    • Search Google Scholar
    • Export Citation
  • 3

    Bentwich Z, Maartens G, Torten D, Lal AA, Lal RB, 2000. Concurrent infections and HIV pathogenesis. AIDS 14 :2071–2081.

  • 4

    Gann P, Neva FA, Gam AA, 1994. A randomized trial of single-and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 169 :1076–1079.

    • Search Google Scholar
    • Export Citation
  • 5

    Kaiser PB, Nutman TB, 2004. Strongyloides stercoralis in the immunocompromised population. Clin Micro Rev 17 :208–217.






View More View Less
  • 1 Department of Microbiology and Infectious Diseases, Flinders Medical Centre, Bedford Park, South Australia, Australia

This case describes the investigation of a man from a country with high endemicity for human immunodeficiency virus (HIV) who was found to have co-infections with implications for management.